Sodiumhexametaphosphate

PreclinicalSmall molecule

MMinia University

Sodiumhexametaphosphate is one of 4 small molecule programs targeting Primary Teeth. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary TeethUnknown status

Primary TeethPreclinical

Unknown status

Competition

Competitive Landscape

4 competitors in Primary Teeth

#DrugCompanyPhaseTrials

Mineral Trioxide Aggregate

JJordan University of Science and Technology

Phase 3

1 2

Silver Diamine Fluoride

TThe University of Hong Kong

Preclinical

2 3

Neoputty MTA

OOctober University for Modern Sciences and Arts

Preclinical

1 4

Sodiumhexametaphosphate

MMinia University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Primary Teeth1 trial

Sodiumhexametaphosphate as Pulp Capping Material for Primary Teeth

Unknown status·MMinia University·N/A·NCT06170775·100 enrolled

Unspecified1 trial

Sodiumhexametaphosphate Versus MTA as Pulp Capping Material for Immature Permanent Teeth

Unknown status·MMinia University·N/A·NCT06170762·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Sodiumhexametaphosphate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sodiumhexametaphosphate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sodiumhexametaphosphate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Minia University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMinia University

Sodiumhexametaphosphate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Primary Teeth1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News